Chemotherapy for prostate cancer

Abstract

For many years the benefit of chemotherapy in patients with prostate cancer was thought to be limited to palliation of late-stage disease, and thus this treatment option only became involved in patient care towards the end of the disease process, if at all. However, two landmark phase-III trials with docetaxel-based therapy (TAX 327 and Southwest Oncology Group, SWOG, 9916) have shown a survival benefit for patients with hormone refractory prostate cancer (HRPC) thus prompting a change in patterns of care. With raising interest for chemotherapeutic options and clinical trials for new drugs and new indications (neoadjuvant therapy, adjuvant therapy, increasing PSA levels after local treatment, and hormone sensitive cancer) under way our goal was to review within the context of a multidisciplinary team the available evidence and explore the standard for the medical treatment of prostate cancer outside of clinical trials. We are carefully evaluating the current treatment recommendations based on the available evidence and highlight potential future treatment options but also discuss important clinical topics (treatment until progression versus the advantage of chemo holidays, definition of particular patient subgroups and potential second line options) for which there are no clear cut answers to date. The role and importance of radiotherapy, biphosphonate treatment and the medical management of pain and side effects is also discussed. The multitude of treatment options for patients with advanced prostate cancer clearly asks for a close collaboration between urologists, medical oncologists and radiation therapists.

Design of Curcumin loaded Cellulose Nanoparticles for Prostate Cancer

“…Chemotherapy is considered a major therapeutic modality in which various natural and synthetic cyto-toxic drugs are used. However, conventional chemotherapeutic approaches are greatly limited due to their low therapeutic index, severe side effects, poor pharmacokinetics and consequent bio-pharmaceutical underperformance in the body [11–14]. In addition, most of these chemotherapeutics are suitable to treat localized androgen-dependent prostate cancers but exhibited limited efficacy in androgen-independent and metastatic prostate cancers [15–17].…”